A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals

BACKGROUND: We conducted a phase 1, randomized, double-blind, placebo-controlled trial of a replication-defective HSV-2 vaccine, HSV529 (deleted for UL5 and UL29), in 60 healthy adults aged 18 to 40 years. METHODS: Subjects were enrolled in groups of 20 from 3 serogroups: HSV1+ or 
-/HSV2+ (group 1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dropulic, Lesia, Wang, Kening, Oestreich, Makinna, Pietz, Harlan, Garabedian, Doreen, Jegaskanda, Sinthujan, Dowdell, Kennichi, Nguyen, Hanh, Laing, Kerry, Koelle, David, Azose, Aaron, Hunsberger, Sally, Lumbard, Keith, Chen, Aiying, Chang, Lee-Jah, Phogat, Sanjay, Cohen, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630753/
http://dx.doi.org/10.1093/ofid/ofx163.1041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630753/
http://dx.doi.org/10.1093/ofid/ofx163.1041

Ejemplares similares